Multi-center, Randomized, Open label Study of the Durability of glycemic control with Nateglinide versus Glimepiride as monotherapy in type 2 diabetic patients.
Phase of Trial: Phase IV
Latest Information Update: 18 May 2017
At a glance
- Drugs Glimepiride (Primary) ; Nateglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Status changed from recruiting to completed.
- 25 Aug 2011 New source identified and integrated (Korean Clinical Trials Register record KCT0000052).